By 2026, the global botulinum toxin market will reach US$7.9 billion

Abstract: The global botulinum toxin market will reach $7. It will reach 9 billion by 2026. Botulinum toxin is a neurotoxin produced by Clostridium botulinum, which can prevent the release of acetylcholine and cause muscle relaxation.
New York, July 14, 2021 (GLOBE NEWSWIRE) – announced the release of the “Global Botox Industry” report- in a controlled laboratory Manufactured under conditions and administered in very small therapeutic doses, BTX is only administered intravenously in the affected area. The growth of the global market is driven by the growing demand for medical/therapeutic and cosmetic applications. Facial injections (such as BTX) are becoming increasingly accepted in adult facial beauty, and the approval of therapeutic BTX to treat a wider range of indications is expected to stimulate market expansion. The continuous development and launch of new products that enhance aesthetic appeal, as well as the growing demand for minimally invasive cosmetic treatments and therapeutic applications, are driving market demand. In the field of neuromuscular therapy, the use of botulinum toxin is driven by the increase in the incidence of sports-related diseases and the increase in the number of patients with muscle spasms. In addition, new clinical indications of botulinum toxin, such as the treatment of nystagmus, stridor, palatine myoclonus, scoliosis, co-spasm after brachial plexus neuropathy (birth-related) and gait freezing (Parkinson), Helps to further strengthen the development of this field. During the COVID-19 crisis, the global market for botulinum toxin in 2020 is estimated to be 4.9 billion U.S. dollars, and it is expected to reach a revised 7.9 billion U.S. dollars by 2026, which is estimated to be 8.2 billion U.S. dollars during the analysis period. % Compound annual growth rate growth. Category A is one of the market segments analyzed in the report. It is expected that by the end of the analysis period, the compound annual growth rate will reach 8.2% and reach USD 8.5 billion. After a thorough analysis of the business impact of the pandemic and the economic crisis it triggered, the growth of the category B market segment was re-adjusted to a revised compound annual growth rate of 6.9% in the next 7 years. Botulinum toxin type A can be used to treat movement disorders, vocal cord dysfunction and obesity, as well as gastric cancer. Botulinum toxin type A is increasingly used in the treatment of cerebral palsy muscle spasm and neurogenic bladder disease in children, which will promote the growth of botulinum toxin type A. Type B is used for various muscle-related diseases. Botulinum neurotoxin type B was approved by the FDA in 2000 for the treatment of adult cervical dystonia to reduce the severity of abnormal head position and neck pain associated with cervical dystonia. The US market in 2021 is estimated to be US$3.1 billion, while China is expected to reach US$665 million by 2026. The US botulinum toxin market is estimated to be US$3.1 billion by 2021. China is the second largest economy in the world. It is estimated that by 2026, the market size is expected to reach 665 million U.S. dollars, with a compound annual growth rate of 14.8% during the analysis period. Other notable geographic markets include Japan and Canada, which are expected to grow by 8.1% and 6.9%, respectively, during the analysis period. In Europe, Germany is expected to grow at a compound annual growth rate of approximately 9.1%. The United States is the largest regional market, mainly due to the continuous increase in approvals for new therapeutic indications. In addition, the increasing focus on improving appearance, the increase in people’s disposable income, and the subsequent increase in demand for cosmetic surgery have also contributed to the growth. The growing demand for non-invasive or minimally invasive cosmetic treatments has also contributed to the growth of the Botox market in the United States. Due to the existence of a large number of cosmetics manufacturers, Europe also provides attractive opportunities for the botulinum market. The rapidly improving socio-economic conditions and the surge in medical tourism, especially in Asian countries, provide a good prospect for the development of botulinum toxin in the Asia-Pacific region. Select a competitor (28 selected in total).

Post time: Jul-16-2021